We develop, manufacture, and deliver protective and life-saving solutions for communities around the world.
Opioid Emergency Preparedness
Emergent distributes NARCAN® Nasal Spray 4 mg and KLOXXADO® (naloxone HCI) Nasal Spray 8 mg to federal and state leaders, community-based organizations, harm reduction groups, law enforcement and first responders through its expansive distribution network.
NARCAN® Nasal Spray is also widely available nationwide as the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose.
For over 25 years, Emergent has been at the forefront of preparedness, working hand in hand with governments and agencies to deliver products that protect against some of the world’s most pressing health threats, including botulism, Ebola, smallpox, mpox and anthrax.
*Individual Named Patient Use may be a potential pathway for a healthcare provider treating an individual patient with an immediately life-threatening condition to gain access to an Emergent product for treatment outside of commercially available means.
*EbangaTM is a trademark of RIDGEBACK BIOTHERAPEUTICS L.P.
**KLOXXADO®is a registered trademark of Hikma Pharmaceuticals USA Inc.
***On April 2, 2024, Emergent submitted its revocation of the Market Authorization for the Trobigard Auto-Injector to the Belgium Federal Agency for Medicines and Health Products (FAMHP). The FAHMP subsequently acknowledged and confirmed the revocation date as being April 2, 2024. As such, Emergent has discontinued production of Trobigard, and the product is no longer available; however, we remain committed to public health preparedness and will continue to work with allied governments to protect soldiers and civilians across the globe.
This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.
